Copyright
©The Author(s) 2016.
World J Hepatol. Aug 8, 2016; 8(22): 933-941
Published online Aug 8, 2016. doi: 10.4254/wjh.v8.i22.933
Published online Aug 8, 2016. doi: 10.4254/wjh.v8.i22.933
Figure 2 F4/80 immunostaining.
Representative images of F4/80 immunostaining (magnification, × 400) of Kupffer cells in the (A) control and (B) ambrisentan groups; C: Numbers of immunopositive F4/80 cells (arrows) in both groups; representative immunostaining for 8-OHdG (magnification, × 400) in the (D) control and (E) ambrisentan groups; F: Comparison of 8-OHdG-immunopositive cells between the groups; immunostaining for 4-HNE (magnification, × 400) in the (G) control and (H) ambrisentan groups; I: Comparison of 4-HNE-immunopositive cells between the groups. 4-HNE: 4-hydroxynonenal.
- Citation: Okamoto T, Koda M, Miyoshi K, Onoyama T, Kishina M, Matono T, Sugihara T, Hosho K, Okano J, Isomoto H, Murawaki Y. Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model. World J Hepatol 2016; 8(22): 933-941
- URL: https://www.wjgnet.com/1948-5182/full/v8/i22/933.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i22.933